Expression and significance of sclerostin in the process of alveolar bone reconstruction in type 2 diabetic rats with periodontitis

doi:10.19438/j.cjoms.2023.01.003

Abstract

Abstract: PURPOSE: To observe the expression of sclerostin in the process of alveolar bone reconstruction in rats with type 2 diabetes (T2DM) and periodontitis. METHODS: Fifty-four SD rats were randomly divided into control group, periodontitis group, and T2DM with periodontitis group with 18 rats in each group. The periodontitis group included a rat model with periodontitis, and the T2DM with periodontitis group included a T2DM model first, and then established a periodontitis model. The glucose metabolism indicators were detected at 1, 5, and 10 days after intraperitoneal injection of STZ. The periodontal indexes were detected at 8 weeks after ligation. The expression of sclerostin in alveolar bone tissue were detected by immunohistochemical staining 1, 3, 6 months after successful modeling. SPSS 21.0 software package was used for data analysis. RESULTS: Compared with unmodeled rats, fasting blood glucose (FBG) at 1, 5, and 10 days after intraperitoneal injection of STZ, fasting serum insulin(FINS) and homeostasis model assessment for insulin resistance (HOMA-IR) at 10 days after intraperitoneal injection of STZ in T2DM model rats were increased (P<0.05). Compared with unmodeled rats, the gingival bleeding index(SBI), plaque index (PLI) and probe depth (PD) in periodontitis model rats were increased(P<0.05). Compared with control group, the expression of sclerostin in the alveolar bone tissue at 1, 3, and 6 months after successful modeling in periodontitis group and T2DM with periodontitis group was increased(P<0.05), which was significantly higher in T2DM with periodontitis group than in periodontitis group (P<0.05). Compared with 1 month after successful modeling, the expression of sclerostin in the alveolar bone tissue at 3, 6 months after successful modeling in periodontitis group and T2DM with periodontitis group was increased(P<0.05). Compared with 3 months after successful modeling, the expression of sclerostin in the alveolar bone tissue at 6 months after successful modeling in periodontitis group and T2DM with periodontitis group was decreased(P<0.05). CONCLUSIONS: The expression of sclerostin is increased in periodontitis, and the expression of sclerostin with T2DM is further up-regulated, but it is gradually down-regulated during the process of bone remodeling.

Key words: Type 2 diabetes mellitus, Periodontitis, Alveolar bone remodeling, Sclerostin

CLC Number:

R782.1

LIU Xiao-dong, ZHANG Ying, MA Jin-yu, LI Yu-zeng. Expression and significance of sclerostin in the process of alveolar bone reconstruction in type 2 diabetic rats with periodontitis[J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(1): 19-23.

References

[1] 杨正祥, 李航, 李鲲. 雷洛昔芬对牙周炎合并系统性绝经后骨质疏松症小鼠模型局部牙槽骨破坏的影响[J]. 中国口腔颌面外科杂志, 2020, 18(5):407-411.
Yang ZX, Li H, Li K.Effect of raloxifene on local alveolar bone destruction of mice with periodontitis and systemic postmenopausal osteoporosis[J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(5): 407-411.
[2] Preshaw PM, Bissett SM.Periodontitis and diabetes[J]. Br Dent J, 2019, 227(7): 577-584.
[3] Eleftheriadou I, Tentolouris A, Anastasiou IA, et al.Factors associated with sclerostin levels-A calcification inhibitor-In individuals with type 2 diabetes mellitus; Is autonomic neuropathy the missing link?[J]. J Diabetes Complications, 2020, 34(10): 107677.
[4] Fabre S, Funck-Brentano T, Cohen-Solal M. Anti-sclerostin antibodies in osteoporosis and other bone diseases[J]. J Clin Med, 2020, 26;9(11): 3439-3455.
[5] 余慧平, 卫宝宁, 孙甫, 等. 人工股骨头置换在高龄股骨转子间骨折中的应用及对髋关节功能的影响[J]. 西部医学, 2019, 31(8): 1247-1251.
Yu HP, Wei BN, Sun P, et al.Application of artificial femoral head replacement in elderly patients with intertrochanteric fracture and its influence on hip joint function[J]. Medical Journal of West China, 2019, 31(8): 1247-1251.
[6] Cole JB, Florez JC.Genetics of diabetes mellitus and diabetes complications[J]. Nat Rev Nephrol, 2020, 16(7): 377-390.
[7] Wu CZ, Yuan YH, Liu HH, et al.Epidemiologic relationship between periodontitis and type 2 diabetes mellitus[J]. BMC Oral Health, 2020, 20(1):204-219.
[8] Genco RJ, Borgnakke WS.Diabetes as a potential risk for periodontitis: association studies[J]. Periodontol 2000, 2020, 83(1): 40-45.
[9] Maré A, D'Haese PC, Verhulst A. The role of sclerostin in bone and ectopic calcification[J]. Int J Mol Sci, 2020, 21(9):3199-3119.
[10] Miyatake K, Kumagai K, Imai S, et al.sclerostin inhibits interleukin-1β-induced late stage chondrogenic differentiation through downregulation of Wnt/β-catenin signaling pathway[J]. PLoS One, 2020, 15(9): e0239651.
[11] Kleber M, Ntanasis-Stathopoulos I, Dimopoulos MA, et al.Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?[J]. Expert Rev Hematol, 2019, 12(8): 651-663.
[12] Kim SP, Frey JL, Li Z, et al.Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes[J]. Proc Natl Acad Sci USA, 2017, 114(52): E11238-E11247.
[13] 严伟, 王中汉, 刘贺. 骨重建失衡导致骨质疏松发生的作用机制及其药物治疗策略[J]. 中国组织工程研究, 2020, 24(30): 4866-4874.
Yan W, Wang ZH, Liu H.Action mechanism of bone remodeling imbalance in osteoporosis and relevant medical treatment strategy[J]. Chinese Journal of Tissue Engineering Research, 2020, 24(30): 4866-4874.
[14] Zhou X, Wang Q, Nie L, et al.Metformin ameliorates the NLPP3 inflammasome mediated pyroptosis by inhibiting the expression of NEK7 in diabetic periodontitis[J]. Arch Oral Biol, 2020, 116: 104763.
[15] Pinho RCM, Pimentel LB, Bandeira FAF, et al.Levels of serum sclerostin, metabolic parameters, and periodontitis in -postmenopausal women with diabetes[J]. Spec Care Dentist, 2017, 37(6): 282-289.
[16] Miranda TS, Napimoga MH, Feres M, et al.Antagonists of Wnt/β-catenin signalling in the periodontitis associated with type 2 diabetes and smoking[J]. J Clin Periodontol, 2018, 45(3):293-302.